Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodiesWilton B. Williams, Barton F. Haynes, John F. Whitesides et al.|Science|2015Cited by 202
Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trialKenneth H. Mayer, Kelly E. Seaton, Yunda Huang et al.|PLoS Medicine|2017Cited by 132
Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 studyYehuda Z. Cohen, Marina Caskey, Allison L. Butler et al.|PLoS ONE|2019Cited by 92
Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like ParticlesPaul Goepfert, Harriet L. Robinson, Marnie Elizaga et al.|The Journal of Infectious Diseases|2014Cited by 84
Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trialK. Rachael Parks, M. Juliana McElrath, Zoe Moodie et al.|Science Translational Medicine|2025Cited by 40